A biomarker concept for assessment of insulin resistance, β-cell function and chronic systemic inflammation in type 2 diabetes mellitus

Clinical Laboratory

Volumn 54, Issue 11-12, 2008, Pages 485-490

  Pfützner, Andreas ^a,b   Weber, Matthias M ^a,b   Forst, Thomas ^a,b  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Adiponectin; HsCRP; Insulin resistance; Intact proinsulin; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; PROINSULIN;

ADIPOGENESIS; ARTICLE; CARDIOVASCULAR RISK; CELL STRESS; CHRONIC INFLAMMATION; DIAGNOSTIC ACCURACY; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE MARKER; EXERCISE; HOMEOSTATIC ASSESSMENT MODEL; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROTEIN BLOOD LEVEL; REPRODUCIBILITY; SCORING SYSTEM;

ADIPONECTIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; PROINSULIN; REPRODUCIBILITY OF RESULTS;

EID: 60549111796     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH: Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992; 15: 666-92.
2. Pfützner A, Forst T. Intaktes Proinsulin als kardiovaskulärer Risikomarker und prädiktiver diagnostischer Marker für die Insulinresistenz bei Patienten mit Typ 2 Diabetes. Diab. Stoffw. 2004; 14: 193-200.
3. Pfützner A, Kann P, Pfützner AH, Kunt T, Larbig M, Weber MM, Forst T. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes. Clin. Lab. 2004; 50: 567-73.
4. Pfützner A, Pansky A, Maiworm A, Matthey M, Lückerath K, Roitzheim B, Forst T, Tobiasch E. Mesenchymal stem cell differentiation into adipocytes is equally induced by insulin and proinsulin in vitro. Diabetologia 2006; 49(Suppl.1): P-707.
5. Smith SA. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. Biochimie 2003; 85: 1219-30.
6. Feher T, Bodrogi L, Vallent K, Ribai Z. Role of human adipose tissue in the production and metabolism of steroid hormones. Endokrinologie. 1982; 80: 173-80.
7. Schöndorf T, Maiworm A, Emission N, Forst T, Pfützner A. Biological Background and Role of Adiponectin as Marker for Insulin Resistance and Cardiovascular Risk. Clin Lab. 2005; 51: 489-94.
8. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome J Intern Med 2005; 257: 167-75.
9. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol. 3:63-68, 2003.
10. Pfützner A, Kunt T, Löbig M, Knesovic M, Forst T. Clinical and Laboratory Evaluation Characteristics of Two New Chemiluminescence Assays for Intact and Total Proinsulin. Clin. Chem. Lab. Med. 2003; 41: 1234-8.
11. Pfützner A, Kunt T, Mondok A, Pahler S, Konrad T, Luebben G, Forst T. Fasting Intact Proinsulin is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes. Diabetes Care 2004; 27: 682-7.
12. Pfützner A, Standl E, Hohberg C, Konrad T, Strotmann HJ, Lübben G, Pahler S, Langenfeld M, Schulze J, Forst T. IRIS II Study: Intact Proinsulin is Confirmed as Highly Specific Marker for Insulin Resistance in a Cross-Sectional Study Design. Diab. Technol. Ther. 2005; 7: 478-86.
13. Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, Forst T. Pioneer Study: PPARγ-Activation Results in an Overall Improvement of Clinical and Metabolic Markers associated with Insulin Resistance independent from Long-Term Glucose Control. Horm. Metab. Res. 2005; 37: 510-5.
14. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of Cardiovascular Risk Markers by Pioglitazone is Independent from Glycemic Control - Results from the Pioneer Study. J. Am. Coll. Card. 2005; 45: 1925-31.
15. Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T. Impact of Rosiglitazone on β-Cell Function, Insulin Resistance and Adiponektin Concentra-tions - Results from a Double Blind Oral Combination Study with Glimepiride. Metabolism 2006; 55: 20-5.
16. Pfützner A, Lorra B, Abdollhania M, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T. Preprandial Short-acting Insulin Analogue Substitution has an Immediate and Comprehensive β-Cell Protective Effect in Patients with Type 2 Diabetes Mellitus - Results from a Randomized Comparator Study vs. Glimepiride. Diab. Technol. Ther. 2006; 8: 375-84.
17. Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab, E-pub Dec 17, 2007.
18. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008; 24: 489-96.
19. Matthews D, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9
20. Guerrero-Romero F, Rodríguez-Morán M, González-Ortiz M, Martínez-Abundis E. Early decrease of the percent of HOMA beta-cell function is independently related to family history of diabetes in healthy young nonobese individuals. Diabetes Metab. 2005; 31: 382-6.
21. Kanauchi M, Nakajima M, Saito Y, Kanauchi K. Pancreatic beta-cell function and insulin sensitivity in Japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism. 2003; 52: 476-81.
22. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
23. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8
24. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008; 294: E15-26
25. http://www.dtu.ox.ac.uk/
26. Langenfeld M, Forst T, Standl E, Strotmann HJ, Luebben G, Pahler S, Kann P, Pfützner A. IRIS II Study: Sensitivity and Specificity of Intact Proinsulin, Adiponectin and the Proinsulin/Adiponectin Ratio as Markers for Insulin Resistance. Diab. Technol. Ther. 2004; 6: 836-43.
27. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
28. Ridker PM, Wilson PF, Grundy SM. Should C-reactive protein beaded to metabolic syndrome and to assessment of global cardiovascular risk. Circulation 2004; 109: 2818-2825.
29. Müller-Rösel M, Tschöpe D. (Dietary options in obesity and metabolic syndrome). Herz. 2006; 31: 220-3.
30. Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2008; 17: 845-53.
31. Mafong DD, Henry RR. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep. 2008; 10: 55-60.
32. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular acions of insulin. Endocrine Rev. 2007; 28: 463-91.
33. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008; 358: 2545-59.
34. ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358: 2560-72.